Background and Objectives. The introduction of high-dose therapy with stem cell support has significantly improved the outcome of patients with multiple myeloma (MM) in terms of increased complete remission (CR) rate extended survival both disease-free overall. Few options however are presently available for patients who relapse after single or double autologous stem cell transplantation (SCT). Thalidomide a glutamic acid derivative with anti-angiogenetic properties has been recently proposed as salvage treatment for such patients. The present study was aimed at evaluating thalidomide as single agent therapy for patients who had previously received autologous peripheral blood stem cell transplantation. Design Methods. From October 1999 to August 2000 11 patients (7 males/4 females) who had relapsed after single (n=4) or double (n=7) autologous peripheral blood SCT were enrolled in the trial. Thalidomide always employed as a single agent was initially administered at a dose of 100 mg/day; if well tolerated the dose was increased serially by 200 mg every other week to a maximum of 800 mg/day. Results. The median administered dose was 600 mg/day. WHO grade > II toxic effects were constipation lethargy leukopenia. Four patients (36%) showed > 50% reduction in serum M protein concentration 4 showed > 25% reduction for a total response rate averaging 72%. After a median follow-up of 5 months 3 out of 8 responding patients are alive and progression-free and 5 patients have relapsed. Interpretation and Conclusions. These data confirm that thalidomide is active in poor-prognosis MM patients such as those relapsing after autologous SCT, and could thus deserve further testing in combination therapy.
|Number of pages||5|
|Publication status||Published - 2001|
- Autologous stem cell transplantation
- Multiple myeloma
ASJC Scopus subject areas